Exercise Performance on Ambient Air vs. Low-Flow Liquid Oxygen Therapy in Chronic Lung Diseases
Recruiting · NCT07777367 · Interventional (participants receive a specific treatment) · Lead sponsor: Silvia Ulrich Somaini
View the official record on ClinicalTrials.gov →Interventions studied
6-minute walk distance (6MWD) test on ambient conditions6-minute walk distance (6MWD) test with supplemental oxygen (LOX)
What this trial is about
The investigators aim to study the effect of liquid oxygen therapy (4l/min, nasal) )in Swiss residents with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH).
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Minimum 18 years of age
- Written informed consent
- Patients with diagnosed pulmonary arterial hypertension (PAH), distal chronic thromboembolic pulmonary hypertension (CTEPH), chronic obstructive pulmonary disease (COPD) with emphysema, COPD without emphysema, or interstitial lung disease
- Former desaturation under exercise defined as SpO2-decrease \>3%
- Treated with a stable drug therapy (with no changes for at least 14 days prior to screening)
Exclusion criteria
- Severe hypoxemia needing supplemental oxygen therapy defined as PaO2 \< 6.9 kPa
- Inability or contraindications to undergo the investigated intervention
- Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, walk disability etc.
Where it is running
1 location listed.
- University Hospital Zurich - Zurich, Canton of Zurich, Switzerland